Replimune Group, Inc. — Director's Dealing 2020

Dec 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2020-12-22

Reporting Person: Coffin Robert (Director, President & Chief R&D Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-22	Common Stock	S	220000	$40.04	Disposed	1804118	Direct

Footnotes

F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,804,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 468,928 of which are exercisable as of the date hereof.